American global pharmaceutical major Pfizer has decided to withdraw its popular Corex brand of cough syrup formulation and extend the brand name to a new product line as part of its revamp plan, a company statement said.
“The company will be launching a series of products as line extensions under the Corex brand name, starting with the first launch in December 2016 and subsequent launches over the next year,” Pfizer said in a statement.
Following the government ban on fixed dose combination of Chlopheniramine Maleate+ Codeine Syrup, Pfizer had discontinued manufacture and sale of its popular cough syrup Corex, which had sales of Rs 244.48 crore in FY 2015-16.
“Pfizer stands by the safety and efficacy of its current Corex Syrup formulation that has been duly approved by the central and state regulator,” the company said.
All the new products under the Corex brand will be introduced with all due regulatory approvals in place, it added.
“Pfizer remains committed to provide a more comprehensive set of solutions in respiratory indications, while ensuring minimal impact towards patients resulting from the discontinuation of manufacturing of the current Corex syrup formulation,” the company said.